FDAnews
www.fdanews.com/articles/72172-decode-paper-in-jama-describes-efficacy-of-dg031

DeCODE Paper in JAMA Describes Efficacy of DG031

May 11, 2005

DeCODE genetics announced the publication of a landmark article by a team of its scientists presenting the results of Phase II clinical studies of DG031, the company's lead compound being developed for the prevention of myocardial infarction, or heart attack.

The results demonstrate that DG031 works to correct a biological perturbation caused by genetic risk factors for heart attack that the company has identified, and lowers levels of well-established biomarkers for risk of heart attack, including C-reactive protein and myeloperoxidase.

The article, titled "Effects of a 5-lipoxygenase-activating protein inhibitor on biomarkers associated with risk of myocardial infarction: a randomized trial," is published in The Journal of the American Medical Association.